Prognostic significance of MGMT promoter methylation in diffuse glioma patients

References

• Alcantara Llaguno SR, Parada LF. Cell of origin of glioma: biological and clinical implications. Br J Cancer. 2016;115:1445–1450.
   PubMed Web of Science ®Google Scholar
• Lee SC. Diffuse gliomas for nonneuropathologists: The new integrated molecular diagnostics. Arch Pathol Lab Med. 2018;142:804–814.
   PubMed Web of Science ®Google Scholar
• Wesseling P, Kros JM, Jeuken J. The pathological diagnosis of diffuse gliomas: towards a smart synthesis of microscopic and molecular information in a multidisciplinary context. Diagn Histopathol. 2011;17:486–494.
   Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Puduvalli VK, Chaudhary R, McClugage SG, et al. Beyond alkylating agents for gliomas: quo vadimus? Am Soc Clin Oncol Educ Book. 2017;37:175–186.
   PubMedGoogle Scholar
• Khan MN, Sharma AM, Pitz M, et al. High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol. 2016;23:e383–e391.
   PubMed Web of Science ®Google Scholar
• Wang H, Xu T, Jiang Y, et al. The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (New York, NY). 2015;17:239–255.
   PubMed Web of Science ®Google Scholar
• Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20:S2–S8.
   PubMed Web of Science ®Google Scholar
• Sarkaria JN, Kitange GJ, James CD, et al. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res. 2008;14:2900–2908.
   PubMed Web of Science ®Google Scholar
• Damia G, D'Incalci M. Mechanisms of resistance to alkylating agents. Cytotechnology. 1998;27:165–173.
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354.
   PubMed Web of Science ®Google Scholar
• Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol. 2018;233:378–386.
   PubMed Web of Science ®Google Scholar
• Li Q, Guo J, Wang W, et al. Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma. Oncol Lett. 2017;14:229–233.
   PubMed Web of Science ®Google Scholar
• Zawlik I, Kita D, Vaccarella S, et al. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol. 2009;19:188–194.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens A-C, Gorlia T, et al. MGMT Gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
   PubMed Web of Science ®Google Scholar
• Mineura K, Yanagisawa T, Watanabe K, et al. Human brain tumor O6-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. Int J Cancer. 1996;69:420–425.
   PubMed Web of Science ®Google Scholar
• Brell M, Tortosa A, Verger E, et al. Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res. 2005;11:5167–5174.
   PubMed Web of Science ®Google Scholar
• Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One. 2012;7:e33449.
   PubMed Web of Science ®Google Scholar
• Illic R, Somma T, Savic D, et al. A survival analysis with identification of prognostic factors in a series of 110 patients with newly diagnosed glioblastoma before and after introduction of the stupp regimen: a single-center observational study. World Neurosurg. 2017;104:581–588.
   PubMed Web of Science ®Google Scholar
• Nikolov V, Stojanović M, Kostić A, et al. Factors affecting the survival of patients with glioblastoma multiforme. J Buon. 2018; 23:173–178.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996.
   PubMed Web of Science ®Google Scholar
• Jesien-Lewandowicz E, Jesionek-Kupnicka D, Zawlik I, et al. High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. Cancer Genet Cytogenet. 2009;188:77–82.
   PubMedGoogle Scholar
• Kalkan R, Atli Eİ, Özdemir M, et al. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Gene. 2015;554:81–86.
   PubMed Web of Science ®Google Scholar
• Thumma SR, Fairbanks RK, Lamoreaux WT, et al. Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol. 2012;10:75.
   PubMed Web of Science ®Google Scholar
• Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of immune system aging. J Clin Invest. 2013;123:958–965.
   PubMed Web of Science ®Google Scholar
• Johnson AA, Akman K, Calimport SRG, et al. The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res. 2012;15:483–494.
   PubMed Web of Science ®Google Scholar
• Yang J, Yu L, Gaiteri C, et al. Association of DNA methylation in the brain with age in older persons is confounded by common neuropathologies. Int J Biochem Cell Biol. 2015;67:58–64.
   PubMed Web of Science ®Google Scholar
• Jung M, Pfeifer GP. Aging and DNA methylation. BMC Biol. 2015;13:7.
   PubMed Web of Science ®Google Scholar
• Thakkar JP, Dolecek TA, Horbinski C, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985–1996.
   PubMed Web of Science ®Google Scholar